<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148098">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02051387</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-IS</org_study_id>
    <secondary_id>2008-008245-38</secondary_id>
    <nct_id>NCT02051387</nct_id>
  </id_info>
  <brief_title>Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study</brief_title>
  <acronym>CBD-IS</acronym>
  <official_title>Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study With Approved Antipsychotics in Vivo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite recent advances in the understanding and treatment of schizophrenia, this
      devastating disease still affects one percent of world's population. Existing antipsychotics
      reduce psychotic symptoms but are generally not very effective in treating so called
      negative symptoms such as blunted affect and social withdrawal or cognitive disturbances due
      to the disease. Furthermore, a significant portion of patients is refractory to all current
      treatments. Therefore new treatment strategies are needed.

      Several studies suggest a strong association between schizophrenia and the endocannabinoid
      system. This system mediates e.g. the pro-psychotic effects of the best-known ingredient of
      the cannabis plant - delta-tetrahydrocannabinol (Δ9-THC). While the pro-psychotic Δ9-THC is
      known to abet the onset of schizophrenia, another, non-psychotomimetic plant ingredient -
      cannabidiol - has recently been shown to exert antipsychotic effects similar to those of one
      of the most effective modern antipsychotics, amisulpride, but it induced significantly less
      side effects.

      In this phase I safety study, the investigators will evaluate the pharmacokinetics,
      pharmacoequivalence, and drug-drug interaction profile with current antipsychotics of a new
      tablet pharmaceutical preparation of cannabidiol in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Plasma levels of cannabidiol</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>up to 10 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum antipsychotic concentration</measure>
    <time_frame>baseline and after seven days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cannabidiol capsule, 200 mg single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol tablet, various dosages</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride and Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interaction between Amisulpride and Cannabidiol CR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine and Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interaction between Olanzapine and Cannabidiol CR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine and Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interaction between Quetiapine and Cannabidiol CR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone and Cannabidiol CR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interaction between Risperidone and Cannabidiol CR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cannabidiol CR and Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cannabidiol CR levels without interaction with antipsychotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol CR</intervention_name>
    <arm_group_label>Cannabidiol CR</arm_group_label>
    <arm_group_label>Amisulpride and Cannabidiol CR</arm_group_label>
    <arm_group_label>Olanzapine and Cannabidiol CR</arm_group_label>
    <arm_group_label>Quetiapine and Cannabidiol CR</arm_group_label>
    <arm_group_label>Risperidone and Cannabidiol CR</arm_group_label>
    <arm_group_label>Cannabidiol CR and Placebo</arm_group_label>
    <other_name>Arvisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <arm_group_label>Amisulpride and Cannabidiol CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <arm_group_label>Olanzapine and Cannabidiol CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <arm_group_label>Quetiapine and Cannabidiol CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <arm_group_label>Risperidone and Cannabidiol CR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cannabidiol CR and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent given by the subject

          -  Both, female and male subjects may participate

          -  Age between 18 and 45

          -  Negative drug screening at the time of screening

          -  Non-smoking

          -  In female participants in fertile age, reliable contraception, which means
             contraception's pearl-index is equal or smaller than 1.

          -  Body Mass Index between 18 and 30

        Exclusion Criteria:

          -  Lack of accountability

          -  Any current psychiatric disorder through the Structured Clinical Interview for DSM-IV
             (SCID) at the time of screening

          -  Pregnancy or lactation phase in female at the time of screening

          -  Any known psychiatric or neurological illness in the participant's history.

          -  Known family history concerning psychiatric disorders

          -  Relevant use of cannabis (which is defined on the present state of knowledge as at
             the most five times lifetime-consumption and no consumption for at least one year)

          -  Severe physical (internal) or neurological illness, especially cardiovascular, renal,
             advanced respiratory, haematological or endocrinological failures or infectious
             diseases (acute hepatitis A, B or C or HIV) assessed at the time of the screening by
             the subject's history, clinical examination and laboratory testing, at the discretion
             of the investigator

          -  Consumption of any illicit drugs (except cannabis in history, see above)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>F. Markus Leweke, MD</last_name>
    <phone>+49 621 1703 2321</phone>
    <email>leweke@cimh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cathrin Rohleder, PhD</last_name>
    <phone>+49 621 1703 2333</phone>
    <email>rohleder@cimh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>BW</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Markus Leweke, MD</last_name>
      <email>leweke@cimh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Pharmacology, University of Cologne</name>
      <address>
        <city>Cologne</city>
        <state>NRW</state>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 30, 2014</lastchanged_date>
  <firstreceived_date>September 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Quetiapine</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
